{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=tenofovir%2Femtricitabine+%28TDF%2FFTC%29&page=7",
    "query": {
      "intervention": "tenofovir/emtricitabine (TDF/FTC)",
      "page": 7
    },
    "page_size": 10
  },
  "pagination": {
    "page": 7,
    "page_size": 10,
    "total_count": 340,
    "total_pages": 34,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=tenofovir%2Femtricitabine+%28TDF%2FFTC%29&page=8&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=tenofovir%2Femtricitabine+%28TDF%2FFTC%29&page=6&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-14T14:13:10.206Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04760691",
      "title": "Pre-Exposure Prophylaxis (PrEP)- Gender Affirming Hormone Therapy (GAHT) Interactions in TGW",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "HIV",
        "Prophylaxis",
        "Transgender"
      ],
      "interventions": [
        {
          "name": "Truvada alone",
          "type": "DRUG"
        },
        {
          "name": "Truvada plus Leuprolide 11.25mg intramuscular injection",
          "type": "DRUG"
        },
        {
          "name": "Truvada plus Estradiol 1 mg",
          "type": "DRUG"
        },
        {
          "name": "Truvada plus Estradiol 6 mg",
          "type": "DRUG"
        },
        {
          "name": "Estradiol 6 mg alone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Johns Hopkins University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 13,
      "start_date": "2021-03-01",
      "completion_date": "2025-03-24",
      "has_results": true,
      "last_update_posted_date": "2026-04-06",
      "last_synced_at": "2026-10-14T14:13:10.206Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04760691"
    },
    {
      "nct_id": "NCT05592613",
      "title": "Next Generation Ingestible Sensors for Medication Adherence Measurement",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "HIV Infection",
        "Adherence, Medication",
        "Adherence, Treatment",
        "Pre-Exposure Prophylaxis",
        "Antiretroviral Therapy"
      ],
      "interventions": [
        {
          "name": "Next-generation Reader and ID-Cap System",
          "type": "DEVICE"
        },
        {
          "name": "Truvada for pre-exposure prophylaxis (PrEP)",
          "type": "DRUG"
        },
        {
          "name": "Biktarvy for antiretroviral therapy (ART)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DEVICE",
        "DRUG"
      ],
      "sponsor": "Brigham and Women's Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 15,
      "start_date": "2023-02-06",
      "completion_date": "2024-07-25",
      "has_results": false,
      "last_update_posted_date": "2024-09-25",
      "last_synced_at": "2026-10-14T14:13:10.206Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05592613"
    },
    {
      "nct_id": "NCT02469246",
      "title": "Switch Study to Evaluate F/TAF in HIV-1 Infected Adults Who Are Virologically Suppressed on Regimens Containing ABC/3TC",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "HIV-1 Infection"
      ],
      "interventions": [
        {
          "name": "F/TAF",
          "type": "DRUG"
        },
        {
          "name": "ABC/3TC",
          "type": "DRUG"
        },
        {
          "name": "ABC/3TC Placebo",
          "type": "DRUG"
        },
        {
          "name": "F/TAF Placebo",
          "type": "DRUG"
        },
        {
          "name": "3rd ARV agent",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Gilead Sciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 567,
      "start_date": "2015-06-29",
      "completion_date": "2019-03-13",
      "has_results": true,
      "last_update_posted_date": "2019-10-25",
      "last_synced_at": "2026-10-14T14:13:10.206Z",
      "location_count": 34,
      "location_summary": "Phoenix, Arizona • Beverly Hills, California • La Jolla, California + 26 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02469246"
    },
    {
      "nct_id": "NCT01345630",
      "title": "Comparative Trial Of Maraviroc Versus Emtricitabine/Tenofovir Both With Darunavir/Ritonavir In Antiretroviral-Naive Patients Infected With CCR5 Tropic HIV 1",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "HIV-1"
      ],
      "interventions": [
        {
          "name": "Maraviroc",
          "type": "DRUG"
        },
        {
          "name": "Emtricitabine/tenofovir",
          "type": "DRUG"
        },
        {
          "name": "darunavir/ritonavir 800/100 mg",
          "type": "DRUG"
        },
        {
          "name": "placebo for emtricitabine/tenofovir",
          "type": "DRUG"
        },
        {
          "name": "placebo for maraviroc",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "ViiV Healthcare",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 813,
      "start_date": "2011-09",
      "completion_date": "2014-01",
      "has_results": true,
      "last_update_posted_date": "2016-01-14",
      "last_synced_at": "2026-10-14T14:13:10.206Z",
      "location_count": 84,
      "location_summary": "Birmingham, Alabama • Hobson City, Alabama • Hayward, California + 45 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Hobson City",
          "state": "Alabama"
        },
        {
          "city": "Hayward",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01345630"
    },
    {
      "nct_id": "NCT06630299",
      "title": "Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Standard of Care in Virologically Suppressed People With HIV-1",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "HIV-1-Infection"
      ],
      "interventions": [
        {
          "name": "ISL/LEN",
          "type": "DRUG"
        },
        {
          "name": "Antiretroviral Combinations",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Gilead Sciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 600,
      "start_date": "2024-10-08",
      "completion_date": "2030-08",
      "has_results": false,
      "last_update_posted_date": "2026-05-29",
      "last_synced_at": "2026-10-14T14:13:10.206Z",
      "location_count": 49,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 41 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Palm Springs",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06630299"
    },
    {
      "nct_id": "NCT00885664",
      "title": "Immune Reconstitution as a Determinant of Adverse Effects to New Antiretroviral Therapy in Persons With Advanced HIV Infection",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "Truvada (tenofovir/emtricitabine)",
          "type": "DRUG"
        },
        {
          "name": "Kaletra (lopinavir/ritonavir)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Cincinnati",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 60,
      "start_date": "2005-10",
      "completion_date": "2010-03",
      "has_results": true,
      "last_update_posted_date": "2022-08-10",
      "last_synced_at": "2026-10-14T14:13:10.206Z",
      "location_count": 1,
      "location_summary": "Cincinnati, Ohio",
      "locations": [
        {
          "city": "Cincinnati",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00885664"
    },
    {
      "nct_id": "NCT00799864",
      "title": "A Study to Evaluate the Pharmacokinetics, Safety, Tolerability, and Antiviral Activity of Rilpivirine (TMC278) in Human Immunodeficiency Virus Infected Adolescents and Children Aged Greater Than or Equal to 6 Years",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "HIV-1"
      ],
      "interventions": [
        {
          "name": "Rilpivirine",
          "type": "DRUG"
        },
        {
          "name": "Zidovudine",
          "type": "DRUG"
        },
        {
          "name": "Abacavir",
          "type": "DRUG"
        },
        {
          "name": "Tenofovir disoproxil fumarate",
          "type": "DRUG"
        },
        {
          "name": "Lamivudine",
          "type": "DRUG"
        },
        {
          "name": "Emtricitabine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Janssen Sciences Ireland UC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "6 Years to 17 Years"
      },
      "enrollment_count": 54,
      "start_date": "2011-01",
      "completion_date": "2022-08",
      "has_results": true,
      "last_update_posted_date": "2024-06-25",
      "last_synced_at": "2026-10-14T14:13:10.206Z",
      "location_count": 2,
      "location_summary": "Syracuse, New York • Memphis, Tennessee",
      "locations": [
        {
          "city": "Syracuse",
          "state": "New York"
        },
        {
          "city": "Memphis",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00799864"
    },
    {
      "nct_id": "NCT02431247",
      "title": "A Study to Evaluate Efficacy and Safety of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Fixed Dose Combination (FDC) Versus a Regimen Consisting of Darunavir/Cobicistat FDC With Emtricitabine/Tenofovir Disoproxil Fumarate FDC in Treatment-naive HIV Type 1 Infected Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Immunodeficiency Virus Type 1, Human"
      ],
      "interventions": [
        {
          "name": "Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide FDC",
          "type": "DRUG"
        },
        {
          "name": "DRV/COBI FDC",
          "type": "DRUG"
        },
        {
          "name": "FTC/TDF FDC",
          "type": "DRUG"
        },
        {
          "name": "D/C/F/TAF FDC - Matching Placebo",
          "type": "DRUG"
        },
        {
          "name": "FTC/TDF FDC Matching Placebo",
          "type": "DRUG"
        },
        {
          "name": "DRV/COBI FDC Matching Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Janssen Sciences Ireland UC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 725,
      "start_date": "2015-07-06",
      "completion_date": "2020-09-30",
      "has_results": true,
      "last_update_posted_date": "2022-09-28",
      "last_synced_at": "2026-10-14T14:13:10.206Z",
      "location_count": 29,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Bakersfield, California + 26 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Bakersfield",
          "state": "California"
        },
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02431247"
    },
    {
      "nct_id": "NCT02285114",
      "title": "Study To Evaluate Emtricitabine/Tenofovir Alafenamide (F/TAF) in Human Immunodeficiency Virus 1 (HIV-1) Infected Children and Adolescents Virologically Suppressed on a 2-Nucleoside/Nucleotide Reverse Transcriptase Inhibitor (2-NRTI)-Containing Regimen",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "HIV-1"
      ],
      "interventions": [
        {
          "name": "F/TAF",
          "type": "DRUG"
        },
        {
          "name": "3rd ARV agent",
          "type": "DRUG"
        },
        {
          "name": "Boosted PIs",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Gilead Sciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Month",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "1 Month to 17 Years"
      },
      "enrollment_count": 41,
      "start_date": "2015-01-20",
      "completion_date": "2024-12-11",
      "has_results": true,
      "last_update_posted_date": "2025-06-27",
      "last_synced_at": "2026-10-14T14:13:10.206Z",
      "location_count": 4,
      "location_summary": "Los Angeles, California • Aurora, Colorado • Philadelphia, Pennsylvania + 1 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02285114"
    },
    {
      "nct_id": "NCT04692077",
      "title": "Safety, Tolerability and Acceptability of Long-Acting Cabotegravir (CAB LA) for the Prevention of HIV Among Adolescent Males",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "Cabotegravir (CAB) tablet",
          "type": "DRUG"
        },
        {
          "name": "CAB LA",
          "type": "DRUG"
        },
        {
          "name": "Tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) tablet",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "17 Years",
        "sex": "MALE",
        "summary": "Up to 17 Years · Male only"
      },
      "enrollment_count": 9,
      "start_date": "2020-02-19",
      "completion_date": "2023-07-07",
      "has_results": true,
      "last_update_posted_date": "2025-05-20",
      "last_synced_at": "2026-10-14T14:13:10.206Z",
      "location_count": 4,
      "location_summary": "Aurora, Colorado • Chicago, Illinois • Boston, Massachusetts + 1 more",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Memphis",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04692077"
    }
  ]
}